oasis 1 oral semaglutide 50 mg obesity lancet 2023 of #semaglutide daily was associated with body weight reduction and improved cardiometabolic risk factors in East Asian adults with overweight or #obesity, with or without type 2 #diabetes. https://ja.ma/41sPiYj Garvey OASIS 4 OW24-Oral Final

First started taking these as a last resort because I was feeling such a lack of energy

In efficacy and dose-response trials, no comparison with placebo reached statistical significance in the efficacy trial

Remarkably, tirzepatide (15 mg per week) reduced body weight by up to 20.9% after 72 weeks [93], which was associated with reduced waist circumference and an overall improvement in individuals clinical profile

Side effects Common side effects of this drug are: Abdominal pain Constipation Decreased appetite Vomiting Nausea Diarrhea Precautions and Warnings Pregnancy Semaglutide safety during pregnancy is uncertain due to limited data

2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

Mounjaro (tirzepatide) targets both GLP-1 and GIP receptors